Experts Discuss Clinical Benefits of Closed Loop Stimulation at Heart Rhythm Congress
BIOTRONIK Physiological Rate Adaption Technology Improves Life of Patient with Severe Syncope Disorder
Dr. Jan Steffel, University Hospital Zurich, Switzerland, opened the symposium by examining what makes Closed Loop Stimulation unique. Dr. Mark Walsh, Bristol Children’s Hospital, UK, followed with a case study that will be published in the Heart Rhythm Journal. The talk ended with Dr. Carel de Cock, University Medical Center, Amsterdam, Netherlands, who asked whether such technology was appropriate for heart failure patients.
Dr. Walsh spoke of his teen patient who experienced debilitating fainting episodes. Since receiving a BIOTRONIK pacemaker with CLS, the patient has returned to school and resumed some normal activities. “This patient suffered from the most severe case of postural orthostatic tachycardia syndrome (POTS) that I’ve ever witnessed,” said Dr. Walsh. “She fainted several times a day and had no quality of life. That completely changed when I upgraded her pacemaker to a BIOTRONIK CLS device. The difference to her health has been remarkable.”
Clinical trials have shown CLS pacemakers to be uniquely capable of detecting the increase in heart muscle contractility that may occur in the early stage of a syncope.1,2,3
“CLS is a fascinating innovation,” commented session chair Dr. Riyaz Kaba, Ashford and St. Peter’s Hospital, and St. George's University Hospitals, greater London, UK. “As it is currently the subject of the B3 and BIOSync clinical trials – I predict it will be strongly embraced by the cardiology community in the coming years.”
CLS rate adaptive technology is exclusively available in BIOTRONIK pacemakers, ICDs and CRT devices. By integrating into the natural cardiovascular control system, CLS determines the appropriate heart rate based on intracardiac impedance measurements. These measurements reflect changes of the cardiac contraction dynamics in reaction to information coming from the autonomic nervous system. CLS provides the most physiological rate response on the market to optimize heart rates under varied circumstances, based not only on physical activity, but also mental stress.
1 Occhetta E, et al. Europace. 2004, 6(6)
2 Palmisano P, et al. Europace. 2012, 14(7)
3 Russo V, et al. Heart. 2013, 99(21)
A global leader in cardio- and endovascular medical technology, BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries. Several million patients have received BIOTRONIK implants designed to save and improve the quality of their lives, or have been treated with BIOTRONIK coronary and peripheral vascular intervention products. Since its development of the first German pacemaker in 1963, BIOTRONIK has engineered many innovations, including Magmaris, the first clinically-proven resorbable magnesium scaffold; BIOTRONIK Home Monitoring; Pulsar, the world's first 4 F compatible stent for treating long lesions; Orsiro, the industry's first hybrid drug-eluting stent; and the world's first implantable cardioverter defibrillators and heart failure therapy devices with ProMRI® technology.
For more information, visit: www.biotronik.com/en-de
Twitter: @BIOTRONIK_UK and @BIOTRONIK_News